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Splenopentin, Arg-Lys-Glu-Val-Tyr (SP-5) and its synthetic analogs; Arg-o-Lys-Glu-Val-Tyr (pentapeptide 1). Lys-Lys-Glu-Val-Tyr (2), D-Lys- 
Lys-Glu-Val-Tyr (3), Arg-Lys-Gly-Val-Tyr (4). and Arg-Lys-Gin-Val-Tyr (5) have been examined for augmentation of human natural killer (NK) 
cell activity and human T-cell transformation response. Pentapeptides 2 and 3 were found to significantly augment he in vitro human NK cell 
activity. However. none of them had any effect on lymphocyte proliferative responses. 
Splenopentin; Thymopoietin; NK cell cytotoxicity; T-cell transformation; Immunomodulator 
1, I~RODUCTION 
I~unomodulatory activity of thymopentin (TP-5) 
and its synthetic analogs has been well established and 
some of them are presently being evaluated clinically 
[l-4]. According to a report from Audhya et al. [5], a 
closely related pentapeptide called splenopentin (SP-5) 
the amino acid sequence of which differs from that of 
TP-5 only at position 3 due to the presence of a Glu 
residue in place of Asp, exhibits a particularly interest- 
ing i~unopharmacological profile. Unlike TP-5, 
splenopentin (Arg-Lys-Glu-Val-Tyr) does not affect 
neuromuscular transmission and induces phenotypic 
differentiation of both T- and B-cell precursors. Re- 
cently, stimulation of the recruitment of epidermal 
Langerhans cells by SP-5 has also been demonstrated 
[6]. In view of these important findings, we undertook 
the synthesis of some novel analogs of SP-5: Arg-D-Lys- 
Glu-Val-Tyr (pentapeptide l), Lys-Lys-Glu-Val-Tyr 
(2), D-Lys-Lys-Glu-Val-Tyr (3), Arg-Lys-Gly-Val-Tyr 
(4) and Arg-Lys-Gln-Val-Tyr (5) for studying their im- 
munopotentiating activity. In the case of analogs 1-3, 
the amino acid Glu has been retained at position 3 and 
modi~cations have been introduced at positions 1 and 
2. However, in analogs 4 and 5 Glu at position 3 has 
been replaced by Gly and Gln residues, respectively, 
with a view to investigate the role of Glu side chain for 
the biological activity of SP-5. Immunostimulating ac- 
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tivity of the new analogs l-5 has been examined for 
augmentation of human NK cell activity and human 
T-cell transformation response. We have found that an- 
alogs 2 and 3 significantly augment human NK cells. 
2. MATERIALS AND METHODS 
2.1. Synthesis ofpentapeptides 
SP-5 and its analogs l-5 were synthesized by the solution phase 
procedure using the 2 + 3 fragment condensation approach. Deblock- 
ing of the protected pentapeptides Boc-Arg(NO,)-Lys(Z)-Glu(OBzl> 
Val-Tyr-OBzl. Z-A&NO,)-p-Lys(Z)-Glu(OBzl)-Val-Tyr-OBzl, Z- 
Lys~Z)-Lys(Z)-Glu(OBzl)-VaI-Tyr-OBzl, Z-D-Lys(Z)-Lys(Z)-Gltt- 
(OBzl)-Val-Tyr-OBzl, Z-Arg(NO~)-Lys~Z)-Gly-Val-Tyr-OBzl and Z- 
Arg(NO~)-Lys(Z)-Gin-Val-Tyr-OBzl afforded SP-5 and the analogs 
1-5 in a pure state. They were characterized as hydr~hlo~de or 
acetate salts with the help of elemental analysis, TLC, HPLC, NMR 
and FAB-MS. 
2.2. NK cell eytotoxierty assay 
NK cell activity was evaluated by a standard “Cr release assay [7]. 
Non-adherent cells were collected by plastic adherence and stimulated 
for 18 h with human recombinant interferon gamma (100 U/ml, 
Cl 105. Genentech Inc. San Francisco, USA) and/or different peptides 
(at 10s6. IO-’ and lO-4 molar concentration) for NK cell augmentation. 
An erythroleukemic cell line K562, labelled with 5’Cr (sodium chro- 
mate in saline; spee. act. 5Q-150 mCiimg BARC, Bombay, India) was 
used as target. Target cells were incubated with effecters at E/T ratio 
of 5O:l for 4 h. Each set was taken in triplicate. The su~rnatant was 
collected and counted in multig~a counter. Data is presented as 
percent cytotoxicity (7). 
2.3. Lymphocyte prol$eratron assay 
Mononuclear cells were separated from peripheral blood of healthy 
donors as described above. Triplicate cultures were set up in 96-well 
flat-bottom plates, each containing 0.2 ml of cell suspension (2 x lo5 
cells) with or without stimulants. The stimulants included phytohaem- 
agglutinin (PHA; 5 yglml, Sigma, USA), and various synthetic pep- 
tides mentioned above. The cultures were incubated for a total of 3 
days and were pulsed with 0.5 ,&i r3H]thymidine (6 Wmmol, BARC, 
Bombay, India) per well during the last 18 h of incubation. Thymidine 
uptake was determined by liquid scintillation counting. 
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Table I 
Effect of SP-5 and its synthetic congeners on in vitro human NK cell activity 
Sr. 
No. 
Peptide Concentration % cytotoxicity % increase* 
(mean + SD.) 
I II III 
1 Control 
IFN 
Arg-Lys-Glu-Val-Tyr (SP-5) 
lO-4 M 
lo-’ M 
1O-6 M 
1O-4 M + IFN 
lo-’ M + IFN 
1O-6 M + IFN 
2 Control 
IFN 
Arg-o-Lys-Glu-Val-Tyr (1) 
1O-4 M 
IO-’ M 
IO-’ M 
1O-4 M + IFN 
lo-’ M + IFN 
1O-6 M + IFN 
3 Control 
IFN 
Lys-Lys-Glu-Val-Tyr (2) 
1O-4 M 
1O-5 M 
1O-6 M 
lO-4 M + IFN 
lo-’ M + IFN 
lo-” M + IFN 
4 Control 
IFN 
o-Lys-Lys-Glu-Val-Tyr (3) 
lO-4 M 
lo-’ M 
lo-” M 
lO-4 M + IFN 
lO-s M + IFN 
IO-” M + IFN 
5 Control 
IFN 
Arg-Lys-Gly-Val-Tyr (4) 
IO-“ M 
lo-’ M 
lO-6 M 
IO- M + IFN 
lo-’ M + IFN 
lO-6 M + IFN 
6 Control 
IFN 
Arg-Lys-Gln-Val-Tyr (5) 
lO-4 M 
IO-’ M 
lO-6 M 
1O-4 M + IFN 
lO-5 M + IFN 
lO-6 M + IFN 
50.8 38.2 45.3 
91.6 80.7 82.3 902 17 
55.1 42.3 47.3 If3 
53.1 35.2 39.5 5+0 
54.6 39.6 43.2 5+2 
91.1 72.3 80.9 6kO 
90.6 78.6 88.6 7kO 
94.4 83.2 85.3 3fO 
41.6 52.3 46.3 
11.1 78.2 66.3 59 + 23 
48.5 45.6 52.3 ** 
51.1 47.3 39.4 ** 
48.2 40.2 45.2 ** 
77.6 80.6 69.9 4+1 
77.6 86.2 73.2 4+3 
76.6 80.1 15.1 4f3 
51.3 46.2 42.1 
78.1 80.6 68.5 62f 11 
60.6 60.2 61.7 31 f 14 
53.2 66.1 60.8 30 f 23 
53.8 60.2 53.6 20f 14 
76.3 80.1 70.3 2fO 
17.4 73.5 71.2 12 f 0 
79.1 75.6 10.5 1 + 0.7 
48.5 52.3 47.0 
85.0 87.0 73.0 65% 10 
66.2 62.3 53.7 23+ 11 
69.4 67.2 55.9 29+ 12 
66.1 62.0 55.8 242 10 
85.4 81.5 76.2 21r2 
80.1 89.2 74.5 2+0 
75.6 72.3 73.8 if0 
41.7 38.7 49.2 
12.5 60.5 82.3 655 8 
43.0 42.3 46.3 6+3 
39.95 40.1 40.8 3fO 
40.9 35.6 48.1 0 
71.5 65.9 85.3 522 
74.9 62.1 19.3 2+0 
72.2 60.3 86.2 4fO 
40.0 46.2 51.3 
71.3 80.6 78.0 65+ 11 
37.0 44.2 50.1 0 
44.5 46.1 39.8 ** 
46.3 40.3 nd ** 
79.3 nd 45.2 ** 
73.4 12.3 62.5 2fO 
72.8 75.1 63.8 2+0 
February 1993 
IFN = 100 U/ml of recombinant human gamma interferon was used, nd = not done. 
* % increase on cytotoxicity was calcolated in relation to control or interferon. Peptide or interferon was 
compared with control and peptide plus interferon was compared with interferon only. For this purpose 
control or interferon cytotoxiclty was considered 100%. 
** Did not show a consistent increase in all 3 experiments. 
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3. RESULTS 
3.1. Augmentation of human NK cells 
SP-5 and its synthetic congeners (l-5) were tested in 
vitro for augmentation of human NK cells. Results of 
three different experiments are presented in Table I. It 
shows that two analogs of SP-5 viz., Lys-Lys-Glu-Val- 
Tyr (2) and n-Lys-Lys-Glu-Val-Tyr (3), show signifi- 
cant in vitro augmentation of human NK cells. How- 
ever, the degree of activation of NK cell activity by these 
peptides was considerably lower than that by human 
interferon gamma. The peptides neither potentiated nor 
inhibited the augmentation of NK cell activity induced 
by gamma interferon. 
3.2. Human lymphocyte transformation test 
SP-5 and its analogs were also tested for their ability 
to stimulate or inhibit human lymphocyte transforma- 
tion. It was observed that neither SP-5, nor its analogs 
either stimulate T-cell proliferation by themselves or 
inhibit the PHA induced [3H]thymidine uptake (data 
not presented). 
4. DISCUSSION 
NK cells are a discrete subset of lymphocytes which 
are capable of killing tumor and virus infected cells in 
a non-MHC restricted manner. As compared to T cells, 
the NK cells do not need any antigenic exposure for 
their activation [8]. Most of the large granular lympho- 
cytes are considered to be NK cells. These are CD3- and 
TCR- but express CD16 and CD56 surface markers 
[9-121. These cells mainly circulate in the peripheral 
blood. Interferons are known to augment NK cells, 
both in vivo as well as in vitro [12-151. Augmentation 
of NK cells by small synthetic peptides such as analogs 
of muramyl dipeptide, thymopoietin fragments and en- 
dorphins has also been reported [16-191. SP-5 is known 
to induce both T- and B-cell precursors [5]. Our results 
show that splenopentin by itself does not have any effect 
on NK cells but substitution of Arg at position 1 in SP-5 
by Lys (2) and D-Lys (3) results in the appearance of 
significant natural killer cell activity (in vitro). Replace- 
ment of Lys at position 2 by D-Lys (analog 1) and Glu 
at position 3 by Gly and Gln residues (analogs 4 and 5) 
renders them inactive. This indicates the importance of 
Lys and Glu residues at positions 2 and 3 for the NK 
cell activity of this series of peptides. To the best of our 
knowledge this is the first report showing in vitro aug- 
mentation of human NK cells by analogs of SP-5. The 
magnitude of augmentation by the two analogs of SP-5 
was considerably lower than interferon gamma, but is 
quite comparable to other peptides reported in the liter- 
ature [16-181. If these in vitro results are substantiated 
by in vivo studies, these compounds may provide a new 
tool for stimulation of innate host resistance, particu- 
larly against cancer and viral infections. 
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